[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhejiang Chinese Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100632803","study-on-serum-transcriptomics-and-metabolomics-in-patients-with-diabetic-peripheral-neuropathy-100632803",false,"NCT07518433","Study on Serum Transcriptomics and Metabolomics in Patients With Diabetic Peripheral Neuropathy","Inclusion Criteria:\n\n* Patients diagnosed with diabetes mellitus (type 1 or type 2)\n* For the diabetic peripheral neuropathy (DPN) group: meet diagnostic criteria for painful diabetic peripheral neuropathy (P-DPN), defined as persistent pain and\u002For paresthesia in both lower limbs, with at least one objective sign of neuropathy (reduced ankle reflex, reduced vibration perception, or abnormal nerve conduction velocity when available), and a DN4 score ≥ 4\n* For the diabetic control (DC) group: patients with diabetes mellitus but no evidence of peripheral neuropathy\n* For the healthy control (HC) group: healthy volunteers without diabetes or neuropathy, matched for sex and age\n* Aged between 18 and 80 years (inclusive)\n* Able to perform activities of daily living independently and cooperate with study procedures\n* No severe cardiac, cerebral, hepatic, renal, or other systemic diseases, and no severe mental illness or cognitive impairment\n* Willing to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Peripheral neuropathy caused by factors other than diabetes, including but not limited to hypothyroidism, alcohol abuse, medications, genetic disorders, or other systemic diseases\n* Presence of limb ulcers, gangrene, or a history of skin ulceration or non-healing wounds\n* Acute diabetic complications such as diabetic ketoacidosis, hyperosmolar hyperglycemic state, lactic acidosis, or severe infections within the past 3 months\n* Severe hepatic or renal impairment, or severe cardiovascular or cerebrovascular diseases (e.g., unstable angina, myocardial infarction, multiple cerebral infarctions, cerebral hemorrhage)\n* Scars or hyperpigmentation at the testing site that may interfere with accurate measurements\n* Pregnancy, breastfeeding, or planned pregnancy during the study period\n* Participation in another interventional clinical trial within 3 months prior to screening\n* For the diabetic control (DC) group: presence of peripheral neuropathy\n* For the healthy control (HC) group: history of diabetes mellitus, peripheral neuropathy, or use of medications affecting neurological function",true,"ALL","18 Years","80 Years",{"count":20,"type":21},90,"ESTIMATED","90 Months","OBSERVATIONAL","This part of the study enrolled 30 sex- and age-matched healthy controls, 30 diabetic patients without peripheral neuropathy, and 30 patients with diabetic peripheral neuropathy (DPN). Blood samples were collected from the participants, and serum was isolated for transcriptomics and untargeted metabolomics analysis using liquid chromatography-mass spectrometry (LC-MS) to characterize the metabolic profile of DPN. Through differential comparison analysis, serum biomarkers associated with DPN were identified and further correlated with clinical parameters. This approach aims to establish early diagnostic markers for DPN and provide scientific evidence for understanding the complex mechanisms underlying DPN, thereby offering new insights into potential therapeutic strategies.",[26,27],"Diabetic Peripheral Neuropathy (DPN)","Pain",[29,27],"Diabetic Peripheral Neuropathy","NOT_YET_RECRUITING","2026-04-06",{"date":33,"type":34},"2026-04-08","ACTUAL",{"date":36,"type":21},"2026-03-20",{"date":38,"type":21},"2027-06-30",{"name":40,"class":41},"Zhejiang Chinese Medical University","OTHER_GOV",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":18,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":42},"100548421","the-treatment-of-postherpetic-neuralgia-in-the-head-and-face-with-superficial-needling-combined-with-electroacupuncture-100548421","NCT06420778","The Treatment of Postherpetic Neuralgia in the Head and Face With Superficial Needling Combined With Electroacupuncture","A Randomized Controlled Study on the Treatment of Postherpetic Neuralgia in the Head and Face With Superficial Needling Combined With Electroacupuncture","Inclusion Criteria:\n\nMeet the diagnostic criteria in the 2016 Chinese Expert Consensus on the Diagnosis and Treatment of Postherpetic Neuralgia; Age 50-80 years (including telangiectasia), gender is not limited; Have a history of herpes zoster on the head and face, and the lesions on the head and face have been healed and subsided, and the symptoms of neuralgia lasted ≥1 month after lesions were healed, with baseline scores of ≥4 on the Facial Pain Profile, and abnormal sensation of the skin around the lesions, pain sensitivity; Be conscious and have a clear sense of pain and discriminative ability; Sign the informed consent to participate in this study voluntarily. Only those who satisfy the above 5 items at the same time can be included in this study.\n\nExclusion Criteria:\n\nthose who did not meet the above diagnostic criteria; herpes zoster occurring in the perineum, or special types such as visceral herpes zoster, meningeal herpes zoster, and generalized herpes zoster; those who were taking oral pregabalin at a dose of less than 0.2 g or more than 0.6 g per day before inclusion to relieve analgesia; those who had a serious adverse reaction to pregabalin, were allergic to acupuncture, or belonged to patients who were within the range of contraindications to electro-acupuncture; Combined with severe cardiac, hepatic, renal damage, epilepsy, head injury, or cognitive dysfunction, aphasia, psychiatric disorders, and other major diseases, who are unable to cooperate with the treatment; Combined with poorly controlled hypertension and diabetes mellitus patients; Pregnant or breastfeeding patients;8.Patients who are currently participating in other studies, and who have been enrolled in other clinical trials within the last 3 months. Anyone who meets any of these criteria will be excluded.","50 Years",{"count":52,"type":21},124,"INTERVENTIONAL",[55],"NA","Based on the inclusion and exclusion criteria, patients with head and face PHN who met the requirements were selected as trial subjects, and the efficacy was clarified in a randomized controlled design trial. The visual analog score VAS was used as the primary evaluation index, and the depression self-assessment scale score , Hamilton depression scale, Pittsburgh sleep quality index scale, and quality of life evaluation scale (SF-36) were used as the secondary evaluation indexes, and oral pregabalin was used as the control group, and the subjects in the pregabalin and the plexus superficial stabbing combined with electroacupuncture groups were observed respectively at the time of Before treatment, immediately after the first treatment, after 2 days of treatment, after 2 weeks of treatment, after 4 weeks of treatment, after 1 month of follow-up after the end of treatment and after 2 months of follow-up after the end of treatment.",[58,59,60],"Postherpetic Neuralgia","Electroacupuncture","Infrared Thermography","RECRUITING","2025-04-02",{"date":64,"type":34},"2025-04-06",{"date":66,"type":34},"2024-07-12",{"date":68,"type":21},"2025-12-31",{"name":40,"class":41},""]